Artemis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The Company’s lead product candidate, Artemisone, is a semi-synthetic artemisinin derivative with potent antiviral and antiparasitic properties. The Company currently is evaluating Artemisone for the treatment of P. falciparum malaria and human cytomegalovirus (CMV) infections, including stem cell transplant CMV, solid organ transplant CMV, and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic diseases.